EE297 Pricing Strategies and Trends of FDA Approved NSCLC Therapies From 2018 to 2023

Abstract

Authors

SY Cheng AJ Ambegaonkar

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×